European Companies Search Engine

EU funding (€3,998,250): Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020 Hor1 Nov 2016 EU Research and Innovation programme "Horizon"

Overview

Text

Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020

The aim of ROADMAP is to provide the foundation for a Europe-wide real world evidence (RWE) platform in AD by piloting multi-modal data integration tools and engaging with all key stakeholder groups for consensual definition of patient outcomes, tools and methods that are actionable and relevant. ROADMAP will leverage best practice and exploit synergies with other projects and initiatives at the national and European levels in pursue of scalable and transferable solutions for dataset characterisation, outcome classification, data standards, data sourcing, software application and guidelines on the handling and interpretation of RWE data. In parallel, the project will deepen understanding of the ethical, legal and social implications (ELSI) and health economics (HE) impact of a RWE approach for a meaningful contribution to the Big Data for Better Outcomes programme in IMI2. The ROADMAP programme will consist of 8 integrated work packages by which the Consortium will work to (1) identify relevant AD outcomes and progression markers; (2) identify and pool AD-related RWE across data sources; (3) develop and validate disease progression models combining diverse datasets and strategies; (4) develop risk/value-based costing and health economics models for HTA/regulators, service providers, industry and carers; (5) establish stakeholder-based guidelines for RWE; (6) develop a communication strategy focussing on the needs of patients and professionals; (7) develop an ELSI framework for the development and application of RWE in AD. The ROADMAP consortium brings together outstanding expertise, experience and traction in the field, including many of Europe’s top institutions, authorities, companies, experts in AD, biomedical informatics and analysis of epidemiologic and routinely collected health data sources, providing direct connections to key initiatives such as DPUK, EMIF, EPAD and others.


Funded Companies:

Company name Funding amount
Aarhus Universitet €212,250
ACADEMISCH ZIEKENHUIS LEIDEN €110,000
AC IMMUNE SA €0.00
AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN €122,000
Alzheimer Europe €176,000
Biogen Idec Ltd. €0.00
CHU Hopitaux de Bordeaux €0.00
Eli Lilly and Company Ltd. €0.00
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM €181,000
F. HOFFMANN-LA ROCHE AG €0.00
Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria de Salut Jordi Gol i Gurina €212,250
GE Healthcare Ltd. €0.00
Goeteborgs Universitet €250,500
H. Lundbeck AS €0.00
Ixico Technologies Ltd. €117,000
Janssen Pharmaceutica N.V. €0.00
Kobenhavns Universitet €252,000
London School of Economics and Political Science €178,500
National Institute for Health and Care Excellence €292,500
NOVARTIS PHARMA AG €0.00
RIJKSUNIVERSITEIT GRONINGEN €50,000
Synapse Research Management Partners SL €188,750
Takeda Development Centre Europe Ltd. €0.00
The Chancellor, Masters and Scholars of the University of Oxford €1,073,500
The University of Edinburgh €291,000
UNIVERSITEIT MAASTRICHT €291,000

Source: https://cordis.europa.eu/project/id/116020

The filing refers to a past date, and does not necessarily reflect the current state.

Creative Commons License The visualizations for "Aarhus Universitet - EU funding (€3,998,250): Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.